Diferencia entre revisiones de «Pyridostigmine»
(Switch SMW query from broadtable to table format for better layout with TOC) |
|||
| (No se muestra una edición intermedia del mismo usuario) | |||
| Línea 39: | Línea 39: | ||
*Neostigmine analogue; competitive cholinesterase inhibitor→ less acetylcholine breakdown→ more available acetylcholine in synapses | *Neostigmine analogue; competitive cholinesterase inhibitor→ less acetylcholine breakdown→ more available acetylcholine in synapses | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Pyridostigmine]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
Revisión actual - 21:57 20 mar 2026
Administration
- Type: Neostimine analogue, cholinesterase inhibitor
- Dosage Forms: oral immediate or extended release, IV
- Routes of Administration: IV, PO
- Common Trade Names:
- As opposed to physostigmine, pyridostigmine does not cross the blood brain barrier, and is thus a poor agent for agitation and CNS complications
Adult Dosing
- Myasthenia gravis: 60-1500 mg PO daily (immediate release) or 180-540mg PO daily (slow-release)
- Reversal of neuromuscular blocking agents: 0.1-0.25 mg/kg IV
- Organophosphate poisoning prophylaxis: 30mg PO q8h
Pediatric Dosing
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk minimal
- Renal dosing: lower dose may be required, titrate to effect
Contraindications
- Allergy to class/drug
- Mechanical bowel or urinary obstruction
Adverse Reactions
Serious
- Cholinergic crisis
- Bradyarrythmia
Common
- Nausea/vomiting, abdominal cramps, diarrhea
- Muscle cramps, fasciculation, asthenia
- Increased bronchial and salivary secretions
Pharmacology
- Half-life: 3 minutes (IV), 200 minutes (oral)
- Metabolism:
- Excretion: Renal
Mechanism of Action
- Neostigmine analogue; competitive cholinesterase inhibitor→ less acetylcholine breakdown→ more available acetylcholine in synapses
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Myasthenia gravis | 60 mg QID (titrate to effect) | Acetylcholinesterase inhibitor (symptomatic) | PO | Adult |